Therapeutic options for visceral leishmaniasis;Options thérapeutiques pour la leishmaniose viscérale

Medecine et Maladies Infectieuses

Volumn 35, Issue SUPPL. 2, 2005, Pages

  Desjeux, P ^a  

^a Institute for Oneworld Health (iOWH)   (France)

Author keywords

Resistance; Treatment; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; WR 60620;

HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; PROPHYLAXIS; QUALITATIVE ANALYSIS; SHORT SURVEY; VISCERAL LEISHMANIASIS;

EID: 20744455490     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(05)80887-X     Document Type: Article

References (6)

1. Desjeux P Leishmaniasis current situation and new perspectives CIMID 27 2004 305 318
2. Marty P, and Rosenthal E Treatment of visceral leishmaniasis: a review of current treatment practices Exp Opin Pharmacotherapy 3 2002 1101 1108
3. Croft SL, and Yardley V Chemotherapy of leishmaniasis Current Pharmaceutical Design 8 2000 319 342
4. Guerin P, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna M, and Bryceson AD Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda The Lancet Infect Dis 2 2002 494 501
5. Murray HW Treatment of visceral leishmaniasis (kala azar): a decade of progress and future approaches Intl J Infect Dis 4 2000 158 177
6. Bryceson AD A policy for leishmaniasis with respect to the prevention and control of drug resistance Trop Med Intl Health 6 2001 928 934